Topic: Thomas Russo
The conventional wisdom after Gilead Sciences' (GILD) recently announced $11 billion takeover of hepatitis drug developer Pharmasset (VRUS) is that...
Executives. . . . Richard E. T. Smith - Vice President, Investor Relations and Corporate Communications. . P. Schaefer Price - Chief Executive...
Hepatitis C continues to be a hot area for drug development. . Shares of the clinical-stage company Pharmasset (VRUS), which is developing three...
Vertex Pharmaceuticals (VRTX) didn't just beat analyst sales predictions for the company's new hepatitis C drug -- it shattered them.. Expected to...
Vertex Pharmaceuticals' (VRTX) and Johnson & Johnson's (JNJ) hepatitis C drug moved a step closer to receiving European approval, setting up...
A just-announced collaboration with Johnson & Johnson (JNJ) is shining a light on Pharmasset's (VRUS) progress in developing hepatitis C...
Brown-Forman Corporation (BF.B) F1Q2011 Earnings Call Transcript September 01, 2010 10:00 am ET. Joining me today are Paul Varga, our President and Chief Executive Officer; Don Berg, Executive Vice President and Chief Financial Officer; and Jane Morreau, Senior Vice President ...
Hasbro, Inc. (HAS) Q2 2010 Earnings Call Transcript July 19, 2010 8:30 am ET. Joining me today are Brian Goldner, President and Chief Executive Officer; David Hargreaves, Chief Operating Officer; and Deb Thomas, Chief Financial Officer.. Heading into Q2, we knew ...
Brown-Forman Corporation (BF.B) F4Q10 (Qtr End 04/30/10) Earnings Call June 09, 2010 10:00 am ET. Joining me today are Paul Varga, our President and Chief Executive Officer; Don Berg, Executive Vice President and Chief Financial Officer, and Jane ...
Alkermes, Inc. (ALKS) F3Q10 (Qtr End 12/31/09) Earnings Call February 04, 2010 4:30 pm ET. Good afternoon and welcome to the Alkermes conference call to discuss our financial results for the third quarter of fiscal 2010, which ended on ...
